Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hepatitis B immune globulin: the US experience
Autore:
Pruett, TL; McGory, R;
Indirizzi:
Univ Virginia Hlth Syst, Charles O Strickler Transplant Ctr, Charlottesville, VA 22908 USA Univ Virginia Hlth Syst Charlottesville VA USA 22908 sville, VA 22908 USA
Titolo Testata:
CLINICAL TRANSPLANTATION
, volume: 14, anno: 2000, supplemento:, 2
pagine: 7 - 13
SICI:
0902-0063(200008)14:<7:HBIGTU>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIVER-TRANSPLANT RECIPIENTS; PASSIVE-IMMUNIZATION; PROPHYLAXIS; IMMUNOGLOBULIN; RETRANSPLANTATION; RECURRENCE; CIRRHOSIS;
Keywords:
antibody; HBIg; hepatitis B; lamivudine; liver; transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Pruett, TL Univ Virginia Hlth Syst, Charles O Strickler Transplant Ctr, Hosp Dr,Barringer BLdg 5543, Charlottesville, VA 22908 USA Univ Virginia HlthSyst Hosp Dr,Barringer BLdg 5543 Charlottesville VA USA 22908
Citazione:
T.L. Pruett e R. McGory, "Hepatitis B immune globulin: the US experience", CLIN TRANSP, 14, 2000, pp. 7-13

Abstract

The increasingly aggressive use of hepatitis B immune globulin (HBIg) in liver transplantation for hepatitis B infected patients has led to a great improvement in this procedure by lowering the incidence of allograft infection. In this article, major US studies on the use of HBIg. are reviewed, including clinical results, clinical failures and problems, and the remaining information still needed for optimal therapy. Several major clinical findings have resulted from these studies. (1) With a high dose of HBIg and continuous use of this agent, it is possible to prevent recurrence in hepatitis B virus DNA-positive patients. (2) It is difficult to predict the required post-transplant dose of HBIg or the recurrence of hepatitis B in allografts. (3) While passive immunization of HBIg can help achieve successful transplants of patients suffering from hepatitis B cirrhosis, there are two typical patterns of failure: allograft infection with wild-type hepatitis B virus in the early perioperative period and with a mutant virus more than 6 months post-transplantation. These problems appear to arise only in patients with pre-transplant viral replication. (4) Combination therapy of HBIg and lamivudine seems promising for further improvement of liver transplantation,(5) There are still unanswered questions concerning the combination strategy: optimal timing, patient selection, duration of therapy, and the risk ofviral mutations and adverse events. In addition, the role of changing immunosuppression protocols in improving transplantation of hepatitis B infected patients has not been determined.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 13:56:35